Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

We recently reported promising clinical activity for a 10-day regimen of decitabine in older AML patients; high miR-29b expression associated with clinical response. Subsequent preclinical studies with bortezomib in AML cells have shown drug-induced miR-29b up-regulation, resulting in loss of transc...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Blum, William, Schwind, Sebastian, Tarighat, Somayeh S., Geyer, Susan, Eisfeld, Ann-Kathrin, Whitman, Susan, Walker, Alison, Klisovic, Rebecca, Byrd, John C., Santhanam, Ramasamy, Wang, Hongyan, Curfman, John P., Devine, Steven M., Jacob, Samson, Garr, Celia, Kefauver, Cheryl, Perrotti, Danilo, Chan, Kenneth K., Bloomfield, Clara D., Caligiuri, Michael A., Grever, Michael R., Garzon, Ramiro, Marcucci, Guido
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2012
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3383015/
https://ncbi.nlm.nih.gov/pubmed/22566605
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-03-413898
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak